pretickt

Is SOLV a good stock to buy?

Solventum Corporation · end-of-day data as of Nov 13, 2026

Solventum
SOLV · $15.14B
$89.08+0.3%
Nov 13, 2026 · close
$85$90SepOctNov9:3016:003 months +1.9%Nov 13 · close
▲ 3
  • MAs4 of 4
  • MACD0.52
  • Sector▲ +15.9%
Neutral
  • Earnings in104d
  • P/E99.0x
  • RSI55
  • Support-2.2%
  • Resistance+2.4%
  • Off 52w high-5.4%
  • Volume0.7x
  • Bollingerupper half
  • News0.00
  • FCF yield0.0%
  • ConsensusHold · 15
  • Trendsideways
  • 52w range$62–$94
  • ATR+3.2%
  • Off ATH-7.3%
  • InsidersNone in 90d
  • MA20×50↑ in ~6d
▼ 3
  • PT$85.60 -3.9%
  • P/E vs own+218.6%
  • P/E vs sector+207.3%

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Solventum a good stock to buy?

Solventum is strong on 4 of the 5 questions about the business. The price is high: 99.0 times its earnings, above its 3-year median of 9.4 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand steady
  2. Advantage hard to copy
  3. Economics very profitable
  4. Execution delivers
  5. Fragility sturdy
  6. Price expensive
DemandDo people want more of what it sells?steady

SOLV sales growth revenue growth

+1%a year, for the last 3 years

Solventum's sales grew 1% a year for 3 years, to $8.32B in fiscal 2025.

SOLV analysts' forecast revenue estimates

-1%the sales they expect next fiscal year, on the last

Analysts expect Solventum's sales to fall 1% to $8.25B in fiscal 2026 (10 analysts).

SOLV competitors

pretickt analysis-3%its sales in 12 months, on a year before

Solventum's sales fell 3% in the 12 months to Sep 30, 2026; West Pharmaceutical Services' grew 13%, ResMed's grew 9%, Baxter's grew 5% and Cooper Companies' grew 5%.

Advantage moatIs it hard to copy?hard to copy

SOLV return on capital ROIC

pretickt analysis21%earned before tax on the money invested in it

Solventum earned 21% before tax on the capital invested in it in the 12 months to Sep 30, 2026; ResMed 34%, West Pharmaceutical Services 28%, Cooper Companies 5% and Baxter -2%.

SOLV margin on each sale gross margin

54%left after making the product

Solventum kept 54% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 49%.

EconomicsDoes it make good money?very profitable

SOLV margin after costs profit margin

25%of sales left after running the business

Solventum's operating margin was 25% in the 12 months to Sep 30, 2026, against 19% in fiscal 2022.

SOLV cash generated free cash flow

$0cash left after investing, last 12 months

Solventum generated $0 of free cash flow in the 12 months to Sep 30, 2026, less than its reported profit.

SOLV profit per share

+222%in its last fiscal year

Solventum's earnings per share grew 222% in fiscal 2025, to $8.88.

ExecutionDoes it deliver what it promises?delivers

SOLV earnings vs estimates

8 of 8quarters above the analysts' estimate

Solventum beat the analysts' profit estimate in each of its last 8 quarters, the latest on Nov 5, 2026.

SOLV insider buying

+$100Kbought, net, by its executives in 12 months

Solventum's executives and directors bought a net $100K of shares in the 12 months to Nov 13, 2026; none sold.

SOLV number of employees

-9%fewer people in a year

Solventum had 10,000 employees at the end of fiscal 2025, 9% fewer than a year before.

Fragility risksCould something break it?sturdy

SOLV financial health Altman Z-score

1.8Altman Z-score, safe above 3

Solventum's Altman Z-score is 1.8 (Nov 13, 2026), between 1.8 and 3, the grey zone.

SOLV quality checks Piotroski score

5 of 9checks passed

Solventum passes 5 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on return on assets, the current ratio, gross margin and sales for its assets.

SOLV biggest customers

under 10%of sales from any one customer

No customer made 10% of Solventum's sales in fiscal 2025.

SOLV shareholders institutional ownership

pretickt analysis
  • Independent Franchise Partners9.3% ▲
  • Vanguard9.2% ▼
  • BlackRock5.6% ▼
903institutions hold it; the largest sold shares

903 institutions hold 74% of Solventum's shares (Jun 30, 2026); Independent Franchise Partners added shares that quarter, Vanguard and BlackRock sold some.

Price valuationIs the price reasonable?expensive

SOLV price vs profit P/E ratio

99.0×a year's earnings

Solventum's P/E ratio is 99.0 (Nov 13, 2026), above its 3-year median of 9.4.

SOLV price vs competitors

pretickt analysis99.0×a year's earnings, against its competitors

Investors pay 99.0 times Solventum's earnings (Nov 13, 2026), more than for West Pharmaceutical Services (46.7), ResMed (21.9) or Cooper Companies (21.4).

SOLV analysts' target price target

-4%to their average target

Analysts' average price target for Solventum is $85.60, 4% below the Nov 13, 2026 close of $89.08.

What is Solventum's P/E ratio?

Solventum's P/E ratio is 99.0 (Nov 13, 2026), above its 3-year median of 9.4. Investors pay 99.0 times Solventum's earnings (Nov 13, 2026), more than for West Pharmaceutical Services (46.7), ResMed (21.9) or Cooper Companies (21.4).

Who are Solventum's biggest competitors?

pretickt compares Solventum with Baxter, Cooper Companies, West Pharmaceutical Services and ResMed. Solventum's sales fell 3% in the 12 months to Sep 30, 2026; West Pharmaceutical Services' grew 13%, ResMed's grew 9%, Baxter's grew 5% and Cooper Companies' grew 5%.

Is Solventum profitable?

Solventum's operating margin was 25% in the 12 months to Sep 30, 2026, against 19% in fiscal 2022. Solventum generated $0 of free cash flow in the 12 months to Sep 30, 2026, less than its reported profit.

Are insiders buying Solventum stock?

Solventum's executives and directors bought a net $100K of shares in the 12 months to Nov 13, 2026; none sold.

Who owns Solventum stock?

903 institutions hold 74% of Solventum's shares (Jun 30, 2026); Independent Franchise Partners added shares that quarter, Vanguard and BlackRock sold some.

How many employees does Solventum have?

Solventum had 10,000 employees at the end of fiscal 2025, 9% fewer than a year before.

Who are Solventum's biggest customers?

No customer made 10% of Solventum's sales in fiscal 2025.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.